Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 Pipeline Review, H1 2018
Summary
Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 Exportin 1 XPO1 or chromosomal maintenance 1 CRM1 is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucinerich nuclear export signal NES and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active RanGTP. Docking of this complex to the nuclear pore complex NPC is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.
Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 2 and 3 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Genetic Disorders, Immunology and Infectious Disease which include indications Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Diffuse Large BCell Lymphoma, Glioblastoma Multiforme GBM, Prostate Cancer, Malignant Mesothelioma, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Myelofibrosis, NonSmall Cell Lung Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenocarcinoma, Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma ALCL, Angioimmunoblastic TCell Lymphoma AITL/Immunoblastic Lymphadenopathy, Bone Sarcoma, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Colorectal Cancer, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Endometrial Cancer, Extranodal Marginal Zone BCell Lymphoma MucosaAssociated Lymphoid Tissue or MALTLymphoma, Fallopian Tube Cancer, Follicular Lymphoma, Hematological Tumor, HighGrade Glioma, Human Immunodeficiency Virus HIV Infections AIDS, Leiomyosarcoma, Liposarcoma, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Multiple Sclerosis, Natural Killer Cell Lymphomas, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, Ovarian Cancer, Peripheral TCell Lymphomas PTCL, Peritoneal Cancer, Primary Mediastinal BCell Lymphoma, Recurrent Glioblastoma Multiforme GBM, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia CLL, Respiratory Syncytial Virus RSV Infections, Rheumatoid Arthritis, SmallCell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Synovial Sarcoma, Systemic Lupus Erythematosus, Thymoma Thymic Epithelial Tumor, Traumatic Brain Injury, Unspecified Influenza Virus Infections and Waldenstrom Macroglobulinemia.
The latest report Exportin 1 Pipeline Review, H1 2018, outlays comprehensive information on the Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1
The report reviews Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics and enlists all their major and minor projects
The report assesses Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Exportin 1 Chromosome Region Maintenance 1 Protein Homolog or XPO1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope